Nitric oxide (NO) is a universal messenger mol-1 This simple molecule appears to occur in virtually every tissue, and impairment of NO bioactivity has been documented in a wide array of diseases.1,2 There are 3 known isoforms of NO synthase (NOS), the enzyme necessary for the production of NO from its substrate, L-arginine.1,2 These isoforms include endothelial NOS (eNOS), found primarily in the endothelium of blood vessels and airway epithelium; neuronal NOS (nNOS), concentrated in nerve endings and in tissues of the central and peripheral nervous systems, as well as skeletal muscle; and inducible NOS (iNOS), expressed in a variety of tissues.2 The eNOS and nNOS isoforms are primarily constitutively expressed and dependent on increased intracellular calcium and calmodulin binding to generate NO, while iNOS is calciumindependent and primarily induced by the presence of inflammatory factors, including cytokines.3,4 All 3 isoforms can be induced, although by varying stimuli, and all 3 can be constitutively expressed in some cells or tissues. 4 Because NO bioactivity plays important physiologic roles in diverse organs including the blood vessels, brain, lungs, liver, kidney, stomach, and the immune, musculoskeletal, and reproductive systems, impairment of NO bioactivity could be an important factor in a wide range of disease states.
1,2The complexity of NO bioactivity, however, makes it difficult to identify its precise functions in many areas, and to target and modulate these actions or pathways therapeutically.1 Under conditions of oxidative stress, inflammation, and ischemia, NO may be produced at excessive levels and become dysfunctional or "uncoupled," reacting R e v i e w P a p e r